Revenue Update on Boston Scientific Corporation(NYSE:BSX)

Boston Scientific Corporation(NYSE:BSX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $2.13B. Analysts estimated a revenue of $2.05B. Earnings per share were $0.27. Analysts had estimated an EPS of $0.27.

In a different note, Guggenheim Securities said it Initiates Coverage on Boston Scientific Corporation, according to a research note issued on Jun 9, 2016. The shares have been rated ‘Buy’ by the firm. On May 23, 2016, BTIG Research said it Downgrades its rating on Boston Scientific Corporation. The shares have been rated ‘Neutral’ by the firm.

Boston Scientific Corporation (BSX) made into the market gainers list on Thursdays trading session with the shares advancing 1.26% or 0.3 points. Due to strong positive momentum, the stock ended at $24.14, which is also near the day’s high of $24.2. The stock began the session at $23.82 and the volume stood at 84,60,686 shares. The 52-week high of the shares is $24.79 and the 52 week low is $14.1801. The company has a current market capitalization of $32,755 M and it has 1,35,68,66,900 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jul 20, 2016, David A Pierce (SVP and President, Endoscopy) sold 2,480 shares at $24.03 per share price.Also, On Jul 20, 2016, Michael P. Phalen (EVP & President, MedSurg) sold 35,000 shares at $24.03 per share price.On Jul 5, 2016, Timothy A. Pratt (EVP, GC & Chief Admin Officer) sold 24,000 shares at $23.39 per share price, according to the Form-4 filing with the securities and exchange commission.

Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Women’s Health and Neuromodulation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Boston Scientific Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Boston Scientific Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.